| Literature DB >> 35704092 |
Maximilian Brunner1, Alaa Zu'bi2, Klaus Weber2, Axel Denz2, Melanie Langheinrich3, Stephan Kersting3, Georg F Weber2, Robert Grützmann2, Christian Krautz4.
Abstract
BACKGROUND: Leakage of rectal anastomoses is one of the most important and feared complications in colorectal surgery. Apart from patient-specific risk factors, technical aspects may influence the occurrence of anastomotic complications. This study investigated whether using single-stapling techniques (SST) instead of the double-stapling technique (DST) for minimal-invasive rectal anastomosis is associated with a lower rate of anastomotic complications.Entities:
Keywords: Colorectal cancer; Colorectal resections; Crossing stapler lines; Double-stapling technique; Rectal anastomosis; Single-stapling technique
Mesh:
Year: 2022 PMID: 35704092 PMCID: PMC9262801 DOI: 10.1007/s00384-022-04197-5
Source DB: PubMed Journal: Int J Colorectal Dis ISSN: 0179-1958 Impact factor: 2.796
Fig. 1Omega suture: a thread placement and penetration site of the anvil rod (dot). b Ligation of the suture results in an omega shape of the linear stapler line, which is now located inside the round knife of the circular stapler
Fig. 2Single-stapling technique using the omega suture [16]: a after the rectum is divided with a linear stapler and a circular stapler is introduced through the anus. b The anvil rod penetrates the closed rectum at the median site of the linear stapler line. c A suture including both ends of the linear stapler line is placed. The thread is moved to the site of the anvil rod. d When the suture is tied, the linear stapler line is approximated around the anvil rod in an omega shape fashion. e The circular stapler is closed and fired, resulting in a complete resection of linear stapler line by the circular stapler. f Inspection of the distal stapler donut to verify complete resection of the linear stapler line (the suture and both ends of the linear stapler line are visible)
Patient demographics
| Mean age (years) [range] | 54.1 [23–86] | 56.9 [23–85] | 51.6 [23–86] | |
| Sex | ||||
| Male | 114 (42) | 53 (41) | 61 (43) | 0.712 |
| Female | 158 (58) | 78 (59) | 80 (57) | |
| BMI (kg/m2) [range] | 26.1 [16.7–49.9] | 26.3 [17.7–49.9] | 25.9 [16.7–38.5] | 0.927 |
| ASA | ||||
| 1 | 44 (16) | 14 (11) | 30 (21) | 0.062 |
| 2 | 196 (72) | 100 (76) | 96 (68) | |
| 3 | 31 (11) | 16 (12) | 15 (11) | |
| 4 | 1 (0) | 1 (1) | 0 (0) | |
| Active smoking | 50 (19) | 26 (20) | 24 (17) | 0.535 |
| Immunosuppression/steroid therapy | 11 (4) | 7 (5) | 4 (3) | 0.364 |
| Comorbidities | ||||
| Diabetes mellitus | 25 (9) | 11 (8) | 14 (10) | 0.681 |
| Coronary heart disease | 18 (7) | 8 (6) | 10 (7) | 0.811 |
| Heart insufficiency | 10 (4) | 4 (3) | 6 (4) | 0.751 |
| Arterial hypertension | 91 (34) | 52 (40) | 39 (28) | |
| Preoperative radio- or/and chemotherapy | 39 (14) | 16 (12) | 23 (16) | 0.388 |
| Previous abdominal surgeries [range] | 1 [0–6] | 1 [0–5] | 1 [0–6] | 0.655 |
| Preoperative laboratory [range] | ||||
| White blood cell count (× 109/l) | 7.0 [2.0–15.7] | 7.0 [2.0–15.0] | 7.0 [3.0–15.7] | 0.684 |
| Hemoglobin (g/dl) | 13.8 [8.0–17.4] | 13.8 [8.0–17.4] | 13.9 [9.7–16.9] | 0.566 |
| CRP (mg/l) | 10 [0–186] | 9 [0–147] | 11 [0–186] | 0.414 |
| Creatinine (mg/dl) | 0.8 [0.4–3.9] | 0.8 [0.5–3.9] | 0.8 [0.4–1.4] | 0.530 |
| Albumin (g/l) ( | 41.7 [26.0–51.5] | 42.1 [35.5–48.8] | 41.4 [26.0–51.5] | 0.782 |
*Not always determined
Surgical parameters
| Indication for surgery | ||||
| Oncological | 116 (43) | 59 (45) | 57 (40) | |
| Rectum | 82 (71) | 37 (63) | 45 (79) | |
| Sigmoid | 31 (27) | 20 (34) | 11 (19) | |
| Descending colon | 3 (2) | 2 (3) | 1 (2) | |
| Non-oncological | 156 (57) | 72 (55) | 84 (60) | |
| Diverticulitis | 86 (55) | 53 (74) | 33 (39) | |
| Endometriosis | 56 (36) | 12 (17) | 44 (52) | |
| Rectal/sigmoid adenoma | 8 (5) | 4 (6) | 4 (5) | |
| Crohn´s disease | 5 (3) | 2 (3) | 3 (4) | |
| Sigmoid perforation | 1 (1) | 1 (1) | 0 (0) | |
| Operative time (min.) | 297 [119–688] | 295 [129–581] | 300 [119–688] | 0.822 |
| Surgical approach | ||||
| Laparoscopic | 184 (68) | 85 (65) | 99 (70) | 0.366 |
| Robotic | 88 (32) | 46 (35) | 42 (30) | |
| Kind of surgery | ||||
| Rectal resection | 139 (51) | 55 (42) | 84 (60) | |
| Rectal + sigmoid resection | 43 (16) | 24 (18) | 19 (14) | |
| Sigmoid resection | 80 (29) | 45 (34) | 35 (25) | |
| Left hemicolectomy | 10 (4) | 7 (5) | 3 (2) | |
| Ostomy | 72 (27) | 24 (18) | 48 (34) | |
| ICG | 14 (5) | 8 (6) | 6 (4) | 0.588 |
| Level of anastomosis (cm) [range] | 9 [3−16] | 9 [3−16] | 8 [3−16] | |
| Intraoperative blood loss (ml) [range] | 157 [10–1400] | 132 [10–1000] | 181 [10–1400] | |
| Intraoperative intravenous fluids (ml) [range] | 3359 [1000–10500] | 3549 [1000–10500] | 3187 [1000–7000] | 0.060 |
Primary endpoint analysis (risk factors for anastomotic leakage)
| Age (years) | 1.011 | 0.979–1.043 | 0.515 | - | - | - |
| Sex | - | - | - | |||
| Male | 1.000 | |||||
| Female | 0.482 | 0.178–1.307 | 0.152 | |||
| BMI (kg/m2) | 1.022 | 0.926–1.127 | 0.672 | - | - | - |
| ASA | - | - | - | |||
| 1/2 | 1.000 | |||||
| 3/4 | 1.000 | 0.218–4.590 | 1.000 | |||
| Smoking | - | - | - | |||
| No | 1.000 | |||||
| Yes | 0.572 | 0.127–2.586 | 0.468 | |||
| Immunosuppression | - | - | - | |||
| No | 1.000 | |||||
| Yes | 3.644 | 0.722–18.387 | 0.117 | |||
| Comorbidities** | - | - | - | |||
| No | 1.000 | |||||
| Yes | 2.062 | 0.769–5.531 | 0.150 | |||
| Preoperative radio- or/and chemotherapy | - | - | - | |||
| No | 1.000 | |||||
| Yes | 2.708 | 0.898–8.169 | 0.077 | |||
| Preoperative white blood cell count (× 109/l) | 1.106 | 0.907–1.349 | 0.319 | - | - | - |
| Preoperative albumin (g/l)*** | 1.171 | 0.901–1.522 | 0.237 | - | - | - |
| Indication for surgery | - | - | - | |||
| Oncological | 1.000 | |||||
| Non-oncological | 0.498 | 0.184–1.350 | 0.171 | |||
| Operative time (Min.) | ||||||
| Protective ostomy | - | - | - | |||
| No | 1.000 | |||||
| Yes | 1.562 | 0.556–4.390 | 0.398 | |||
| Level of anastomosis (cm) | 0.932 | 0.816–1.063 | 0.292 | - | - | - |
| Intraoperative blood loss (ml) | - | - | - | |||
| Intraoperative intravenous fluids (ml) | 1.000 | 1.000–1.001 | 0.031 | 1.000 | 1.000–1.001 | 0.104 |
| Stapling technique (SST vs. DST) | ||||||
| SST | ||||||
| DST | ||||||
*Inclusion of parameters, if p-value was < 0.05 in univariate analysis; **including diabetes mellitus, coronary heart disease, heart insufficiency, and arterial hypertension; ***reduced number (n = 93) in analysis due to missing data
Secondary endpoint analysis (perioperative outcomes)
| Morbidity (30 days)* | ||||
| I | 8 (3) | 1 (1) | 7 (5) | 0.120 |
| II | 21 (8) | 11 (8) | 10 (7) | |
| IIIa | 3 (1) | 1 (1) | 2 (1) | |
| IIIb | 18 (6) | 5 (4) | 13 (9) | |
| IV | 3 (1) | 2 (2) | 1 (1) | |
| Overall | 54 (20) | 20 (15) | 34 (24) | |
| Mortality (30 days) | 1 (0) | 0 (0) | 1 (1) | 1.000 |
| Length of hospital stay | 9.1 [5–51] | 8.7 [5–51] | 9.4 [5–39] | |
| Readmission | 9 (3) | 1 (1) | 8 (6) | |
| Anastomotic leakage** | 17 (6) | 4 (3) | 13 (9) | |
| Anastomotic stenosis** | 9 (3) | 1 (1) | 8 (6) | |
*According to Clavien-Dindo classification; **mean follow-up 36 months [range 4–75 months]